FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068337799> ?p ?o ?g. }

• W2068337799 endingPage "1200" @default.
• W2068337799 startingPage "1199" @default.
• W2068337799 abstract "We read with interest the article by Rinne et al.,1 who prospectively evaluated 100 consecutive high risk melanoma patients with whole-body positron emission tomography (PET) and conventional diagnostics. In 52 cases (Group A), PET was performed for primary staging. In 48 cases (Group B), there was clinical suspicion of progression, and therefore PET was performed for restaging during the follow-up. The authors concluded that PET “is a highly sensitive and specific technique for melanoma staging, with exception of the brain.” This study is particularly important because it is the first large prospective study to apply PET in the primary staging of melanoma patients. The authors define “high risk melanoma” as a tumor thickness of at least 1.5 mm and Clark Level IV. However, the mean Breslow thickness of the primary lesions is not mentioned, nor is the range. What is “high risk”? This discussion dates from the 1970s, when the term “high risk” was introduced.2 An elective lymph node dissection, performed on melanoma patients with Breslow thickness 1.5–4.0 mm, has shown to confer little, if any, survival advantage. The risk of metastases varies strongly according to thickness, and we think the term “high risk” is relative and needs reevaluation based on current knowledge, particularly regarding lymphatic dissemination. We agree with the authors that the earliest possible detection of metastases at a potentially curable stage is a major objective. PET appears to be very useful in Group B. However, in Group A, PET detected lymph node metastases in only 8% of patients, whereas no systemic metastases were found. With this percentage taken into account, we wonder if PET is sensitive enough for accurate regional staging. Biopsy of the first tumor-draining, sentinel lymph node (SN) is the most recent developed method for the detection of early micrometastases in the regional lymph nodes.3 SN biopsy, which was not mentioned in the article by Rinne et al., has the potential to become the procedure of choice in the regional staging of melanoma patients. With the SN biopsy, we found lymph node metastases in 28% and 67% of Stage I melanoma patients with Breslow thickness 1.51–4.0 and >4.0 mm, respectively,4 and this finding was confirmed by many others. It is not imaginary that a significant number of small metastases were missed by PET. Unfortunately, the sizes of the nine lymph node metastases detected by PET were not reported in the article. Borgstein et al. studied the size and distribution of tumor metastases within 50 tumor positive SN.5 They discovered that with an SN biopsy, micrometastases as small as 0.0005 mm2 could be detected. From subsequent lymph node dissections it became clear that in 75% of cases the SN was the only tumor positive lymph node, with a median metastasis area of 0.15 mm2. It is unclear, but very unlikely, that micrometastases smaller than 1 mm2 can be detected by 18F-fluorodeoxyglucose PET. Practical support for this is found in a recent study by Macfarlane et al.6 In summary, we think that SN biopsy is to be preferable for initial regional staging of Stage I melanoma. The SN biopsy has a lower detection limit (theoretically, one cell) and no risk of false-positivity, and it is obtainable in more hospitals than PET. In our opinion, the diagnostic accuracy of both SN biopsy and PET imaging needs to be prospectively studied in a large group of (unselected) patients with a higher prevalence of lymphatic metastases at presentation (Breslow thickness >3.0 or 4.0 mm). In a broader sense, the still-unknown prognostic relevance of detection of micrometastatic lymph node involvement could affect the place of either technique in the clinical management algorithm. G. Sophie Mijnhout M.D.*, Rik Pijpers M.D.*, Otto S. Hoekstra M.D., PhD.*, G. Jaap J. Teule M.D., PhD.*, Paul J. Borgstein M.D. , Sybren Meijer M.D., PhD. , * Department of Nuclear Medicine, Academisch Ziekenhuis van de Vrije Universiteit, Amsterdam, The Netherlands, Department of Surgical Oncology, Academisch Ziekenhuis van de Vrije Universiteit, Amsterdam, The Netherlands" @default.
• W2068337799 created "2016-06-24" @default.
• W2068337799 creator A5002449160 @default.
• W2068337799 creator A5022185636 @default.
• W2068337799 creator A5070413088 @default.
• W2068337799 creator A5076930840 @default.
• W2068337799 creator A5085091074 @default.
• W2068337799 creator A5087967286 @default.
• W2068337799 date "1999-03-01" @default.
• W2068337799 modified "2023-10-14" @default.
• W2068337799 title "Primary staging and follow-up of high risk melanoma patients with whole-body18F-fluorodeoxyglucose positron emission tomography" @default.
• W2068337799 cites W1667002384 @default.
• W2068337799 cites W2090933434 @default.
• W2068337799 cites W2106510402 @default.
• W2068337799 cites W3180270935 @default.
• W2068337799 doi "https://doi.org/10.1002/(sici)1097-0142(19990301)85:5<1199::aid-cncr28>3.0.co;2-1" @default.
• W2068337799 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9576286" @default.
• W2068337799 hasPublicationYear "1999" @default.
• W2068337799 type Work @default.
• W2068337799 sameAs 2068337799 @default.
• W2068337799 citedByCount "79" @default.
• W2068337799 countsByYear W20683377992012 @default.
• W2068337799 countsByYear W20683377992013 @default.
• W2068337799 countsByYear W20683377992014 @default.
• W2068337799 countsByYear W20683377992015 @default.
• W2068337799 countsByYear W20683377992016 @default.
• W2068337799 countsByYear W20683377992017 @default.
• W2068337799 countsByYear W20683377992019 @default.
• W2068337799 countsByYear W20683377992023 @default.
• W2068337799 crossrefType "journal-article" @default.
• W2068337799 hasAuthorship W2068337799A5002449160 @default.
• W2068337799 hasAuthorship W2068337799A5022185636 @default.
• W2068337799 hasAuthorship W2068337799A5070413088 @default.
• W2068337799 hasAuthorship W2068337799A5076930840 @default.
• W2068337799 hasAuthorship W2068337799A5085091074 @default.
• W2068337799 hasAuthorship W2068337799A5087967286 @default.
• W2068337799 hasBestOaLocation W20683377991 @default.
• W2068337799 hasConcept C121608353 @default.
• W2068337799 hasConcept C126322002 @default.
• W2068337799 hasConcept C126838900 @default.
• W2068337799 hasConcept C141071460 @default.
• W2068337799 hasConcept C146357865 @default.
• W2068337799 hasConcept C151730666 @default.
• W2068337799 hasConcept C188816634 @default.
• W2068337799 hasConcept C2775842073 @default.
• W2068337799 hasConcept C2775862295 @default.
• W2068337799 hasConcept C2777658100 @default.
• W2068337799 hasConcept C2779013556 @default.
• W2068337799 hasConcept C2780283643 @default.
• W2068337799 hasConcept C2780849966 @default.
• W2068337799 hasConcept C2989005 @default.
• W2068337799 hasConcept C502942594 @default.
• W2068337799 hasConcept C71924100 @default.
• W2068337799 hasConcept C86803240 @default.
• W2068337799 hasConceptScore W2068337799C121608353 @default.
• W2068337799 hasConceptScore W2068337799C126322002 @default.
• W2068337799 hasConceptScore W2068337799C126838900 @default.
• W2068337799 hasConceptScore W2068337799C141071460 @default.
• W2068337799 hasConceptScore W2068337799C146357865 @default.
• W2068337799 hasConceptScore W2068337799C151730666 @default.
• W2068337799 hasConceptScore W2068337799C188816634 @default.
• W2068337799 hasConceptScore W2068337799C2775842073 @default.
• W2068337799 hasConceptScore W2068337799C2775862295 @default.
• W2068337799 hasConceptScore W2068337799C2777658100 @default.
• W2068337799 hasConceptScore W2068337799C2779013556 @default.
• W2068337799 hasConceptScore W2068337799C2780283643 @default.
• W2068337799 hasConceptScore W2068337799C2780849966 @default.
• W2068337799 hasConceptScore W2068337799C2989005 @default.
• W2068337799 hasConceptScore W2068337799C502942594 @default.
• W2068337799 hasConceptScore W2068337799C71924100 @default.
• W2068337799 hasConceptScore W2068337799C86803240 @default.
• W2068337799 hasIssue "5" @default.
• W2068337799 hasLocation W20683377991 @default.
• W2068337799 hasLocation W20683377992 @default.
• W2068337799 hasOpenAccess W2068337799 @default.
• W2068337799 hasPrimaryLocation W20683377991 @default.
• W2068337799 hasRelatedWork W1581661267 @default.
• W2068337799 hasRelatedWork W2005291918 @default.
• W2068337799 hasRelatedWork W2017341378 @default.
• W2068337799 hasRelatedWork W2023965343 @default.
• W2068337799 hasRelatedWork W2090463034 @default.
• W2068337799 hasRelatedWork W2397595750 @default.
• W2068337799 hasRelatedWork W2404725347 @default.
• W2068337799 hasRelatedWork W2411929923 @default.
• W2068337799 hasRelatedWork W2413940477 @default.
• W2068337799 hasRelatedWork W2414655467 @default.
• W2068337799 hasVolume "85" @default.
• W2068337799 isParatext "false" @default.
• W2068337799 isRetracted "false" @default.
• W2068337799 magId "2068337799" @default.
• W2068337799 workType "article" @default.